Editas Medicine, Inc. (EDIT)

NASDAQ

$2.37

$-0.06

(-2.47%)

Pre-Market

Editas Medicine, Inc. (EDIT) Live Price Chart

Last updated: ⁦2026-10-20 09:30:40⁩. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.

Summary

Editas Medicine, Inc. (EDIT) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $2.37, with a market capitalization of $360.91M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.66 to $4.28. This page covers its latest market performance, valuation, price trends and company information.

Key Market Data

Market Cap	$360.91M
Open	$2.42
Day's High	$99.95
Day's Low	$0.91
Previous Close	$2.42
Volume	57.89K
Average Volume	2.56M
P/E Ratio	--
52-Week High	$4.28
52-Week Low	$1.66
Dividend Yield	--
Earnings Date	--

Editas Medicine, Inc. (EDIT) Pre-Market Stock Price

Editas Medicine, Inc. (EDIT) is trading at $2.37 in pre-market trading as of 2026-10-20 09:07:00, down 2.27% ($0.05) from the previous close of $2.42

Pre-market trading shows how investors are pricing EDIT before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.

Editas Medicine, Inc. (EDIT) 7-Day Stock Price Change

Over the past seven days, Editas Medicine, Inc. (EDIT) moved from $2.90 to $2.37, representing a decline of 18.45% ($0.53).

The stock traded between $2.25 and $2.97 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.

The average daily volume was 2.16 million shares, down versus the previous seven-day period, indicating lower trading activity.

EDIT 52-Week Price Position

Position in Range: 27.0%

52W Low$1.66

52W High$4.28

EDIT is currently trading at $2.37, placing it 27.0% of the way from its 52-week low of $1.66 to its 52-week high of $4.28. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.

What is Editas Medicine, Inc. (EDIT)?

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.

Editas Medicine, Inc. Information

Industry	BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees	87
Exchange	NASDAQ
Company Website	https://www.editasmedicine.com

How to Buy Editas Medicine, Inc. (EDIT) Stock on MEXC

Eligible investors can buy real shares of Editas Medicine, Inc. (EDIT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.

Step 1: Open and Verify Your RealStocks Account

Log in to the MEXC App, go to Trade → RealStocks, and select Open Account. Complete the required account-opening and identity verification process with MEXC's partner licensed broker.

Step 2: Transfer USDT to Your RealStocks Account

Go to Wallets → RealStocks and transfer USDT from your Spot Account to your RealStocks Account. RealStocks are quoted in USD, while account funding can be completed using USDT.

Step 3: Search for EDIT and Place Your Order

Open the RealStocks trading page and search for EDIT. Select a market or limit order, enter the price and quantity as required, review the order details, and submit your order. Once filled, the corresponding real shares will be held in your RealStocks Account.

Frequently Asked Questions (FAQ)

1.What is Editas Medicine, Inc. (EDIT) stock price today?

Editas Medicine, Inc. (EDIT) is currently trading at $ 2.37, down 2.27% ($0.05) from the previous close of $ 2.42. Intraday prices update in real time during regular trading hours.

2.Is EDIT stock going up or down today?

As of 2026-10-20 09:07:00, EDIT is trading at $ 2.37, down 2.27% ($0.05) from its previous close of $ 2.42. The stock has traded between $ 0.91 and $ 99.95 during today’s regular session. Past price movements do not guarantee future results.

3.What is EDIT pre-market price?

As of 2026-10-20 09:07:00, EDIT is trading at $ 2.37 in pre-market trading, down 2.27% ($0.05) from the previous close of $ 2.42. Pre-market prices reflect trading activity before the regular session opens and may experience lower liquidity and higher volatility.

4.What is EDIT after-hours price?

As of 2026-10-20 09:07:00, EDIT is trading at $ 2.43 in after-hours trading, up 0.21% ($0.00) from the regular-session close of $ 2.42. After-hours prices may differ from the regular session’s opening price due to lower liquidity and wider bid-ask spreads.

5.Is EDIT stock trading now?

EDIT trades on the NASDAQ exchange during regular hours, Monday through Friday, 9:30 AM to 4:00 PM ET, excluding public holidays. Pre-market and after-hours trading are also available through select brokers outside these hours.

6.Where does EDIT sit relative to its 52-week high and low?

Over the past 52 weeks, EDIT has traded between a low of $ 1.66 and a high of $ 4.28. At $ 2.37, the stock is positioned 27.0% of the way from its 52-week low to its 52-week high, providing context for its current price within the one-year trading range.

7.What sector is Editas Medicine, Inc. in?

Editas Medicine, Inc. (EDIT) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector. Sector classification helps investors compare it with companies exposed to similar market trends and competitive conditions.

8.What is Editas Medicine, Inc.'s market capitalization and where is it listed?

Editas Medicine, Inc. is listed on the NASDAQ exchange with a market capitalization of $ 360.91M. Market cap reflects the total market value of all outstanding shares and is commonly used to classify stocks by size.

9.How is EDIT valued in terms of P/E ratio and EPS?

EDIT trades at a P/E ratio of --, based on trailing-twelve-month EPS of $ -0.48. P/E ratio compares the stock price to earnings per share and is a common starting point for assessing valuation relative to peers.

10.Does Editas Medicine, Inc. pay a dividend?

Editas Medicine, Inc. pays an indicated annual cash dividend of $ 0.00 per share, with a current dividend yield of 0.00% based on the latest share price. Dividend policies are subject to change at the board's discretion.